FDA: Ignore the false racial equity argument for keeping Makena
A pharma company is arguing that Makena should be kept on the market because it may work in Black people. But it doesn't work in any people.
Source: statnews.com
Stay updated with breaking news from Adeza Biomedical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A pharma company is arguing that Makena should be kept on the market because it may work in Black people. But it doesn't work in any people.
The drug Makena doesn't reduce the risk of preterm birth, a study found, and the FDA recommended it be taken off the market. Its maker has refused.